luspatercept data present 13thintern symposium myelodysplast syndrom lower risk myelodysplast syndrom patient luspatercept increas hemoglobin level enabl transfus patient becom transfus independ acceleron pharma inc nasdaqxlrn clinic stage biopharmaceut compani focus discoveri develop commerci novel therapeut candid regul cellular growth repair today announc preliminari data ongo phase 2 clinic trial luspatercept patient lower risk myelodysplast syndrom mds data show luspatercept increas hemoglobin level enabl mani patient becom transfus independ present given morn uwe platzbeck md univers hospit dresden germani oral session titl best clinic trial ii mds foundat 13 thintern symposiumon mds acceleron collabor partner celgen corpor joint develop luspatercept excit result lower risk mds patient confirm extend previous find said uwe platzbeck md professor hematolog head mds program univers hospit dresden germani coordin princip investig luspatercept pacemd studi luspatercept may use earli treatment lower risk mds patient either initi treatment anemia patient respond becom refractori treatment erythropoiesi stimul agent key preliminari data present highlight ongo phase 2 clinic trial fulli enrol data 44 58 patient avail efficaci analys 17 44 patient enrol expans cohort use plan phase 3 dose regimen whose data previous present luspatercept general welltoler major advers event ae mild moder grade 1 2 two possibl relat serious advers event muscl pain worsen general conditionin higher dose group 075 175 mgkg administ subcutan everi three week 54 achiev intern work group iwg hematolog improvementerythroidhi threshold efficacy36 patient receiv red blood cell transfus 8 week prior treatment studi achiev transfus independ least 8 week studi ring sideroblast rs type abnorm red blood cell rbc precursor cell bone marrow ring sideroblast associ ineffect erythropoiesi anemia least 15 cell mds patient bone marrow ring sideroblast patient consid rs posit least 30 mds patient rs posit proport like even greater within lower risk segment mds patient rs posit patient higher dose group treat luspatercept63 achiev iwg hie39 achiev transfus independ present slide dr platzbeck talk avail acceleron websit public tababout luspaterceptluspatercept modifi activin receptor type iib fusion protein act ligand trap member transform growth factorbeta tgf superfamili involv late stage erythropoiesi red blood cell product luspatercept regul latestag erythrocyt red blood cell precursor cell differenti matur mechan action distinct erythropoietin epo stimul prolifer earlystag erythrocyt precursor cell acceleron celgen joint develop luspatercept part global collabor luspatercept current phase 2 clinic trial patient betathalassemia patient myelodysplast syndrom inform pleas visit myelodysplast syndromesmd heterogen group hematolog malign bone marrow common lead sever chronic anemia due ineffect erythropoiesi nation cancer institut estim 10000 peopl diagnos mds unit state year patient mds often hypercellular bone marrow various dysplast chang cell also seen peripher blood result cytopenia low blood cell count increas risk progress acut myeloid leukemia near mds patient suffer anemia anemia mds often character high endogen level epo drive abund earli stage red blood cell precursor inabl precursor cell proper differenti healthi function red blood cell mani patient therefor unrespons administr erythropoietin correct result anemia instead requir red blood cell transfus increas risk infect ironoverload relat toxicitiesabout acceleronacceleron clinic stage biopharmaceut compani focus discoveri develop commerci novel therapeut candid regul cellular growth repair compani leader understand biolog tgf protein superfamili larg divers group molecul key regul growth repair tissu throughout human bodi target pathway develop import new medicin acceleron built high product rd platform generat innov clinic preclin protein therapeut candid novel mechan action therapeut candid potenti signific improv clinic outcom patient cancer rare diseas inform pleas visit pharma inckevin f mclaughlin presid chief financi offic ormediasudacommun llcmaureen l suda 5853879248 